Navigation Links
Lotus Pharmaceuticals Announces Business Reorganization and Provides Updates on the Beijing Headquarters Building
Date:1/4/2012

BEIJING, Jan. 4, 2012 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTCBB: LTUS) ("Lotus" or the "Company"), a profitable developer, manufacturer and seller of medicine and drugs in the People's Republic of China ("PRC"), today announced it entered into an agreement to dispose its Inner Mongolia branch company, including land use right for the 1000 Mu (approximately 165 acre) land in Inner Mongolia, in order to focus its business on the Beijing wholesale market.

Pursuant to the agreement with Meng Xin Vegetable Product Company (Meng Xin), the previous owner of the land use right for this tract of land, Lotus Pharmaceuticals will transfer ownership of Liang Fang Pharmaceutical, Ltd. Inner Mongolia branch company and certain assets and liabilities to Meng Xin. The assets, valued at approximately $52.6 million (based on RMB6.298/$), include the entire 1000 Mu land and building thereon (valued at approximately $44.5 million), approximately $7.3 million of account receivables, and three retail drug stores in Beijing (Feng Tai store, Yong An Zhong Sheng store, and He Ping Li store). The liabilities, also valued at approximately $52.6 million, include all tax payable and late payment fees, land use taxes and compensation to farmers which are collected retroactively, unpaid utilities and sewage, as well as management fees to the local government. Meng Xin will receive the assets and assume the liabilities after the transaction. There is no cash payment between Lotus and Meng Xin.

Chairman and Chief Executive Officer Mr. Zhongyi Liu stated, "Because we have not undertaken development of the 1000 Mu land in Inner Mongolia as stipulated in the original agreement when we made the purchase in 2008, we are subject to some significant taxes and penalties, which are collected retroactively. As a result, we could not afford to hold the land any more. In addition, our decision to dispose of the Inner Mongolia branch and the 1000 Mu land is based on our strategic decision to focus on the Beijing wholesale market once the headquarters building is put into use. The transaction enables us to reduce current liabilities, which is very important to us as our resources are currently tied to the operation of the new headquarters building in Beijing."

Separately, the Company started moving into its new headquarters building in Beijing's Chaoyang district at the end of December 2011. This over 34,000 square meter multi-story building will host the Company's key divisions, including manufacturing, R&D, sales and marketing, storage warehouse, and administrative offices. The Company expects the new storage warehouse to become functional by March 2012.

Mr. Liu commented, "We expect the storage warehouse in the new headquarters building will be put into use by March, and the manufacturing facility by the end of Q3 of 2012, after inspection and certification are completed. With these new facilities, we anticipate additional capacity for growth and significant efficiency improvements in the coming years."

About Lotus Pharmaceuticals, Inc.

Lotus Pharmaceuticals, Inc. is a profitable developer and producer of drugs and a licensed national seller of pharmaceutical items in the People's Republic of China (PRC). Lotus operates its business through its two controlled entities: Liang Fang Pharmaceutical, Ltd. and En Ze Jia Shi Pharmaceutical, Ltd. Lotus' current drug development is focused on the treatment of cerebro-cardiovascular diseases, asthma and diabetes. Liang Fang sells drugs directly and indirectly through its national sales channels to hospitals, clinics and drugs stores in 30 provinces of the PRC.

Information Regarding Forward-Looking Statements

Except for historical information contained herein, the statements in this press release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause our actual results in future periods to differ materially from forecasted results. These risks and uncertainties include, among other things, product demand, market competition, and risks inherent in our operations. These and other risks are described in our filings with the U.S. Securities and Exchange Commission.

Contacts:

Xing Shen, Ph.D.
VP of Corporate Development
Lotus Pharmaceuticals, Inc.
Ph: 415-690-7688
Email: shen@lotuspharma.com
Web: http://www.lotuspharma.com


'/>"/>
SOURCE Lotus Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lotus Pharmaceuticals Announces Third Quarter 2011 Financial Results
2. Lotus Pharmaceuticals Announces Second Quarter Fiscal 2011 Financial Results
3. Lotus Pharmaceuticals to Expand Construction of Beijing Facility
4. Lotus Pharmaceuticals Provides Inner Mongolia Land Price Guidance from Cha You Qian Qi Government
5. Lotus Pharmaceuticals Announces Approval of Reverse Stock Split
6. Lotus Pharmaceuticals Announces Change of Directors
7. Lotus Pharmaceuticals Announces Update on Land in Inner Mongolia
8. Lotus Pharmaceuticals Announces Conference Call to Discuss Third Quarter 2010 Financial Results
9. Lotus Pharmaceuticals Preparing to Apply for National Exchange Listing
10. Lotus Pharmaceuticals Retains Sichenzia Ross Friedman Ference LLP as General Legal Counsel
11. Lotus Pharmaceuticals Announces Two Senior Management Appointments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... Dec. 6, 2016 Two new disaster drones ... a simulated mass casualty event Tuesday at John Bell ... technology debuted before an audience including Mississippi ... from Homeland Security, Federal Law Enforcement Agencies, and the ... as HiRO (Health Integrated Rescue Operations), was developed by ...
(Date:12/6/2016)... , Dec. 6, 2016  Arcturus Therapeutics, Inc. ... company, announced today that it entered into collaboration ... therapeutics for the treatment of NASH and other ... delivery platform LUNAR™ and UNA Oligomer chemistry. The ... Takeda,s long-standing commitment to and expertise in GI ...
(Date:12/6/2016)... Dec. 6, 2016  Blueprint Medicines Corporation (NASDAQ: ... targeted kinase medicines for patients with genomically defined diseases, ... offering of $125,000,000 million in shares of its common ... underwriters a 30-day option to purchase up to an ... stock in connection with the public offering. All shares ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... ... “Fred Rides a Train” allows readers to tag along on a special shopping trip ... the creation of published author, Janet Morrison, who has been writing mostly poetry, essays, ... Dog" series is her first attempt at writing for children. Janet, Fred, and two ...
(Date:12/7/2016)... ... 2016 , ... The Business Architecture Guild is ... on March 21-22, 2017. This premier event features business practitioners and experts from ... of industries such as financial services, insurance, healthcare, manufacturing, transportation, retail, and utilities. ...
(Date:12/7/2016)... ... December 07, 2016 , ... NuevaCare, a leading home care ... proud to announce new city-specific pages as part of its ambitious website relaunch. As ... often look, first, for local agencies serving their city. The new site has several ...
(Date:12/6/2016)... ... December 06, 2016 , ... People with ... be seen on a type of MRI, according to a study appearing online ... the central nervous system characterized by tremors or trembling and stiffness in the ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... of a higher risk of serious health problems, such as cardiovascular illness, according ... Peiman Soleymani of Beverly Hills Periodontics & Dental Implant Center notes that the ...
Breaking Medicine News(10 mins):